Artificial Intelligence, Machine Learning, and Deep Learning in the Diagnosis and Management of Hepatocellular Carcinoma

Carolina Larrain,Alejandro Torres-Hernandez,Daniel Brock Hewitt

DOI: https://doi.org/10.3390/livers4010004

2024-01-09

Livers

Abstract:Artificial Intelligence (AI) can be a useful tool in the management of disease processes such as hepatocellular carcinoma (HCC) as treatment decisions are often complex and multifaceted. AI applications in medicine are expanding with the ongoing advances in AI including more sophisticated machine learning and deep learning processes. In preliminary studies, AI algorithms have demonstrated superiority in predicting the development of HCC compared with standard models. Radiomics, a quantitative method used to extract features from medical imaging, has been applied to numerous liver imaging modalities to aid in the diagnosis and prognostication of HCC. Deep learning methodologies can help us to identify patients at higher likelihood of disease progression and improve risk stratification. AI applications have expanded into the field of surgery as models not only help us to predict surgical outcomes but AI methodologies are also used intra-operatively, in real time, to help us to define anatomic structures and aid in the resection of complex lesions. In this review, we discuss promising applications of AI in the management of HCC. While further clinical validation is warranted to improve generalizability through the inclusion of larger and more diverse populations, AI is expected to play a central role in assisting clinicians with the management of complex disease processes such as HCC.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to apply artificial intelligence (AI), machine learning (ML) and deep learning (DL) technologies in the diagnosis and management of hepatocellular carcinoma (HCC) in order to improve diagnostic accuracy, improve risk stratification, optimize treatment decisions, and enhance the accuracy of prognostic assessment. Specifically, the paper explores the following aspects:

1. **Screening and Detection**: The paper discusses how to use AI technology to improve early screening and detection methods for HCC, especially in low - resource settings. These technologies can provide non - invasive and resource - efficient means to reliably screen and detect HCC. For example, by using deep - learning models to extract features from imaging data to improve the ability to identify HCC.

2. **Prognosis and Recurrence Risk**: It has studied how to integrate multi - omics data through AI technology to identify more aggressive HCC subtypes and predict the risk of patient recurrence. This helps to better guide clinical treatment decisions, especially for patients after surgery.

3. **Pathological Evaluation**: It has explored the application of AI in pathology, such as predicting the recurrence risk of HCC through whole - slide imaging and the potential of predicting the response to immunotherapy based on histological images.

4. **Locoregional Treatment**: It has studied the application of AI models in selecting patients suitable for locoregional treatment (such as radiofrequency ablation) to predict treatment effects.

Overall, this paper aims to demonstrate the multiple potential applications of AI technology in HCC management, emphasizing the potential of these technologies in improving diagnostic accuracy, optimizing treatment options and improving patient prognosis. At the same time, the paper also points out the limitations of current AI technology in medical applications and proposes possible future improvement directions.